Columbus Circle Investors’s Alexion Pharmaceuticals ALXN Stock Holding History

Columbus Circle Investors’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-188,836	Closed	-$21M	–	224
2018 Q1	$21M	Sell	188,836 -42,966	-19%	-$5.14M	0.43%	93
2017 Q4	$27.7M	Sell	231,802 -51,546	-18%	-$6.28M	0.53%	73
2017 Q3	$39.8M	Buy	283,348 +203,358	+254%	+$27.6M	0.68%	49
2017 Q2	$9.73M	Buy	79,990 +4,194	+6%	+$488K	0.16%	127
2017 Q1	$9.19M	Buy	75,796 +13,183	+21%	+$1.7M	0.13%	154
2016 Q4	$7.66M	Sell	62,613 -46,402	-43%	-$5.68M	0.1%	170
2016 Q3	$13.4M	Sell	109,015 -8,023	-7%	-$1.03M	0.14%	129
2016 Q2	$13.7M	Sell	117,038 -485,571	-81%	-$68.9M	0.14%	146
2016 Q1	$83.9M	Sell	602,609 -204,193	-25%	-$30M	0.75%	43
2015 Q4	$154M	Buy	806,802 +252,128	+45%	+$44M	1.23%	23
2015 Q3	$86.7M	Buy	554,674 +13,943	+3%	+$2.54M	0.71%	44
2015 Q2	$97.7M	Sell	540,731 -152,879	-22%	-$26.4M	0.69%	43
2015 Q1	$120M	Buy	693,610 +214,642	+45%	+$38.9M	0.82%	36
2014 Q4	$88.6M	Buy	478,968 +310,627	+185%	+$57.6M	0.63%	47
2014 Q3	$27.9M	Buy	168,341 +29,930	+22%	+$4.92M	0.2%	118
2014 Q2	$21.6M	Buy	+138,411	New	+$21.9M	0.15%	140
2014 Q1	–	Sell	-35,793	Closed	-$4.76M	–	341
2013 Q4	$4.76M	Sell	35,793 -235,428	-87%	-$28.3M	0.03%	248
2013 Q3	$31.5M	Sell	271,221 -90,369	-25%	-$9.91M	0.22%	121
2013 Q2	$33.4M	Buy	+361,590	New	+$34.8M	0.27%	103

Other funds holding ALXN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Columbus Circle Investors's ALXN Position: Q2 2018 in Review

Columbus Circle Investors sold out of Alexion Pharmaceuticals (ALXN) in Q2 2018, closing a stake of 188,836 shares — an estimated $21M sold.

Columbus Circle Investors first reported a position in ALXN in Q2 2013 and held it in 19 quarters. The position peaked at $154M in Q4 2015. 600 funds tracked by Wall St. Rank hold ALXN as of Q2 2018.

Columbus Circle Investors reported no remaining Alexion Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
Columbus Circle Investors sold 188,836 Alexion Pharmaceuticals shares in Q2 2018, an estimated $21M.
Columbus Circle Investors first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 19 quarters.
Columbus Circle Investors's Alexion Pharmaceuticals position peaked at $154M in Q4 2015.
600 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2018.

Based on Columbus Circle Investors's 13F filing for Q2 2018, filed 24 Jul 2018.